This drug affected neither the enhanced blood pressure levels (Figure S3) or cardiac hypertrophy (and the compensatory increase of systolic function) evoked by AngII (Table S2), excluding any influence of hemodynamic or cardiac effects on the observed responses. The gene discussed is AGT; the disease is cardiac hypertrophy.